# AbbVie to Present Data on Seven Solid Tumor Assets at ESMO 2026 in Madrid

> AbbVie will present new and updated data on seven solid tumor assets at ESMO 2026 in Madrid, including Temab-A, ABBV-706 and Elahere.

- Published: 2026-10-18T22:28:42+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-10-18/abbvie-esmo-2026-solid-tumor-data
- Source: [PR Newswire](https://www.prnewswire.com/news-releases/abbvie-to-present-data-at-the-2026-european-society-for-medical-oncology-esmo-congress-highlighting-progress-across-its-expanding-solid-tumor-portfolio-302911997.html)

## Key takeaways

- AbbVie will present new and updated data on seven solid tumor assets at the 2026 ESMO Congress in Madrid on October 23-27.
- Temab-A plus bevacizumab showed a 30% overall response rate and median overall survival of 14.7 months in previously treated advanced colorectal cancer.
- ABBV-706 achieved a 56% overall response rate and 12.4-month median overall survival in relapsed or refractory small cell lung cancer.

[AbbVie](https://akta.pro/company-profiles/00000r2/abbvie) will present new and updated data on seven solid tumor assets at the 2026 European Society for Medical Oncology Congress, taking place October 23-27 in Madrid, Spain. The company announced the presentations on October 18, 2026, according to [PR Newswire](https://www.prnewswire.com/news-releases/abbvie-to-present-data-at-the-2026-european-society-for-medical-oncology-esmo-congress-highlighting-progress-across-its-expanding-solid-tumor-portfolio-302911997.html). The data span lung, colorectal, ovarian, prostate and gastric cancers.

## AbbVie's Seven Assets at ESMO 2026

AbbVie said the presentations represent its most expansive ESMO program to date. The assets include Temab-A (telisotuzumab adizutecan), ABBV-706, ABBV-969, ABBV-1480 (RC148), alveltamig, Elahere (mirvetuximab soravtansine-gynx) and Emrelis (telisotuzumab vedotin-tllv).

In a Phase 1 study of previously treated advanced colorectal cancer, pooled data from the safety lead-in and dose-optimization cohorts showed Temab-A at 2.4 mg/kg with bevacizumab demonstrated a 30% overall response rate and median overall survival of 14.7 months after a median follow-up of 18.2 months, compared with 10.2 months for standard of care. In non-squamous non-small cell lung cancer, Temab-A showed a 50% overall response rate and median overall survival of 13.8 months in patients with EGFR wild-type disease, and a 63% overall response rate and 16.2-month median overall survival in patients with EGFR-mutant disease.

"The data we are presenting at ESMO reflects the progress being made through AbbVie's disciplined, biology-driven approach to oncology innovation," said Daejin Abidoye, vice president, therapeutic area head of oncology, solid tumor and hematology, AbbVie.

ABBV-706, a SEZ6-directed ADC, achieved a 56% overall response rate and 12.4-month median overall survival at the selected Phase 3 dose of 1.8 mg/kg in 2L+ small cell lung cancer patients. In the 2L-only subset, the overall response rate increased to 82% with a 14.4-month median overall survival.

## AbbVie's Oncology Pipeline and Scale

AbbVie is a global biopharmaceutical company developing and commercializing medicines across immunology, oncology, neuroscience, virology, eye care and aesthetics, according to [akta.pro company records](https://akta.pro/company-data). The same records show AbbVie reported 12.4% revenue growth to $15.0 billion in Q1 2026 despite a 40.3% decline in legacy Humira sales, and that Skyrizi and Rinvoq combined generated $7.29 billion in Q1 2026, up 16% year over year.

## Earlier AbbVie Oncology and Research News

On October 13, 2026, AbbVie received FDA Breakthrough Therapy Designations for Temab-A in colorectal and lung cancer, alongside new data for Skyrizi, Rinvoq and obesity candidate ABBV-295, according to Simply Wall St. On October 15, 2026, AbbVie and Genmab reported positive topline Phase 3 EPCORE DLBCL-2 results for epcoritamab plus R-CHOP in newly diagnosed DLBCL, showing a 51% reduction in disease progression or death versus R-CHOP alone, according to Yahoo. On October 17, 2026, AbbVie presented 20 new scientific abstracts on its IBD portfolio at the 2026 UEG Week in Barcelona, according to Stock Titan.

## What Comes Next for AbbVie

AbbVie's Q3 earnings are expected on October 30, according to MarketBeat. The ESMO Congress runs October 23-27 in Madrid.

## Companies in this story

- [AbbVie company profile](https://akta.pro/company-profiles/00000r2/abbvie) · website: https://www.abbvie.com

---
News for Agent · https://newsforagent.com/llms.txt